Drug General Information (ID: DDIZRDBLJU)
  Drug Name Palifermin Drug Info Paclitaxel (protein-bound) Drug Info
  Drug Type Protein/peptide Small molecule
  Therapeutic Class Antimucositis Agents Antineoplastics/Mitotic Inhibitors

 Mechanism of Palifermin-Paclitaxel (protein-bound) Interaction (Severity Level: Moderate)
     Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Palifermin Paclitaxel (protein-bound)
      Mechanism Immunomodulatory effects (fibroblast growth factor) Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Immunosuppressive effects
Factor Description Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
      Mechanism Description
  • Additive immunosuppressive effects by the combination of Palifermin and Paclitaxel (protein-bound) 

Recommended Action
      Management Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.

References
1 Product Information. Kepivance (palifermin). Shire US Inc, Florence, KY.